Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RXRG001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RXRG001 Part 1 | EXPERIMENTAL | Open-label, single arm with 6 subsequent dose cohorts (3 single dose and 3 multiple dose cohorts) of RXRG001 administered intraductally in the salivary gland (unilateral) |
| RXRG001 Part 2 | EXPERIMENTAL | Randomized double-blind with 3 subsequent multiple dose cohorts. RXRG001 is administered intraductally in the salivary gland (bilateral) |
| Placebo Part 2 | PLACEBO_COMPARATOR | Randomized double-blind with 3 subsequent multiple dose cohorts. Placebo is administered intraductally in the salivary gland (bilateral) |
| Name | Type | Description |
|---|---|---|
| RXRG001 | BIOLOGICAL | Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle |
| Placebo | BIOLOGICAL | Placebo (saline) |
Inclusion Criteria\* 1. At least 18 years of age 2. Free from recurrence of your cancer and never have had another form of cancer for at least 2 years 3. Suffering from xerostomia and/or hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months 4. Bot...